Yuko Omori

Yuko Omori

Auto-generated profile, based on publicly available information

Yuko Omori

Department of Investigative Patholgy, Tohoku University Graduate School of Medicine, Sendai, Japan

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2019 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
KNKazumasa Nagai
Kazumasa Nagai
YMYusuke Mizukami
Yusuke Mizukami
YOYuko Omori
Yuko Omori
TKToshifumi Kin
Toshifumi Kin
KYKei Yane
Kei Yane
AKAkio Katanuma
Akio Katanuma

27 July 2023 in Journal of Clinical Pathology
Verified
Journal Article
Closed access
PDF file
YOYuko Omori
Yuko Omori
TFToru Furukawa
Toru Furukawa
ASAldo Scarpa
Aldo Scarpa
Claudio LuchiniClaudio Luchini
Claudio Luchini
Intraductal papillary mucinous neoplasm (IPMN) of the pancreas is one of the most well-established precursors of pancreatic cancer. Its progression to acquire invasiveness is a complex process, based on the accumulation of morphological and genetic alterations. Recent advances in DNA sequencing also showed that co-occurring IPMNs and pancreatic cancers could be totally independent, further complicating our understanding of this complex scenario. The distinction between IPMN and related pancreatic cancer vs IPMN and co-occurring—but not related—pancreatic cancer is a challenging task in routine diagnostic activity, but may have important implications for precision oncology. Of note, recent multiregional sequencing-based studies focused not only on IPMN multi-step tumourigenesis, but also on the divergent intratumoural heterogeneity of this neoplasm. Globally considered, there are three different situations in which co-occurring IPMNs and invasive carcinomas can be found in the same pancreata, indicated with different terminologies: (1) IPMN-associated carcinoma: this definition indicates a carcinoma arising from an IPMN and can be also defined as IPMN-derived carcinoma, sequential or likely related; (2) independent IPMN and invasive carcinoma: the two lesions are not related, and this situation is defined as concomitant, de novo or likely independent; (3) branch-off pathway, where an invasive carcinoma and an adjacent IPMN develop divergently in a forked fashion from a common ancestral clone. In this review, we aim at clarifying the most important nomenclature/definitions of these different situations, also providing an overview of the molecular state-of-the-art and of the clinical implications of this complex landscape.